早期淋巴细胞采集用于抗CD19 CAR-T制备可改善复发/难治性弥漫大B细胞淋巴瘤患者的T细胞适合度
这项前瞻性研究比较了首次复发时早期淋巴细胞采集(早期组,n=22)与标准采集(第二次复发及以后,标准组,n=23)对CD19-CAR-T输注的复发/难治性弥漫大B细胞淋巴瘤患者临床结局的影响;早期组初始T细胞比例和体外T细胞功能增加、耗竭特征降低,但未转化为显著改善的临床结局,观察到总生存和无进展生存有改善趋势。
要点
- 早期组(n=22)初始T细胞比例和体外T细胞功能增加,耗竭特征低于标准组(n=23)。
- T细胞表型和功能改善未转化为显著改善的临床结局。
- 观察到总生存和无进展生存有改善趋势。
核心结论
- 早期淋巴细胞采集可最大化挽救治疗的潜力,且不损害CAR-T细胞质量。
- 淋巴细胞采集产物中T细胞表型和功能的改善未转化为显著改善的临床结局,但观察到总生存和无进展生存有改善趋势。
研究设计与样本
- 前瞻性研究,比较首次复发时早期淋巴细胞采集(早期组,n=22)与第二次复发及以后标准采集(标准组,n=23)对CD19-CAR-T输注的复发/难治性弥漫大B细胞淋巴瘤患者临床结局的影响。
主要发现
- 早期组初始T细胞比例增加,体外T细胞功能增加。
- 早期组T细胞耗竭特征低于标准组采集的T细胞。
- T细胞表型和功能改善未转化为显著改善的临床结局。
- 观察到总生存和无进展生存有改善趋势。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Chimeric antigen receptor (CAR) T cells targeted to the CD19 B-cell antigen form an approved treatment for patients with relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL). However, since this therapy is administered after multiple lines of treatment and exposure to lymphotoxic agents, there is an urgent need to optimize this modality of treatment. METHODS: To circumvent the difficulties of harvesting adequate and optimal T cells from DLBCL patients and improve CART therapy, we suggest an earlier lymphopheresis (i.e. at first relapse, before salvage treatment). We conducted a prospective study and evaluated the potential benefit of an earlier lymphopheresis (early group, n = 22) on the clinical outcome of CD19-CART infused DLBCL patients, in comparison with standard lymphopheresis (i.e. at second relapse and beyond; standard group, n = 23). RESULTS: An increased percentage of naïve T cells and increased in vitro T-cell functionality were observed in the early group. Additionally, these cells exhibit a lower exhaustion profile than T cells collected in the standard group. CONCLUSION: While improved T-cell phenotype and function in the lymphopheresis product did not translate into significantly improved clinical outcomes, a trend towards better overall survival (OS) and progression-free survival (PFS) was observed. Early lymphopheresis maximizes the potential of salvage therapies, without compromising CAR T-cell quality.
引用
- Dubnikov Sharon T, Assayag M, Avni B, et al. Early lymphocyte collection for anti-CD19 CART production improves T-cell fitness in patients with relapsed/refractory diffuse large B-cell lymphoma. Br J Haematol. 2023. PMID: 37070396. doi:10.1111/bjh.18816
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。